https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-10-05 / Front Immunol 2021;12:721830
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-10-05 / Front Immunol 2021;12:7218302021-10-05 00:00:002022-01-10 09:06:12Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-10 / Front Oncol 2021;11:672508
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-10 / Front Oncol 2021;11:6725082021-05-10 00:00:002021-05-10 00:00:00Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-03-13 / J Neurooncol 2021 May;152(3):419-428
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-03-13 / J Neurooncol 2021 May;152(3):419-4282021-03-13 00:00:002021-03-13 00:00:00Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-25 / Neuro Oncol 2021 02;23(2):240-250
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-25 / Neuro Oncol 2021 02;23(2):240-2502021-02-25 00:00:002021-11-15 19:08:36DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-01 / Neurosurg Focus 2021 02;50(2):E8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-01 / Neurosurg Focus 2021 02;50(2):E82021-02-01 00:00:002021-02-01 00:00:00The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)2020-12-24 00:00:002021-11-15 13:17:14Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-11 / Int J Mol Sci 2020 Dec;21(24)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-11 / Int J Mol Sci 2020 Dec;21(24)2020-12-11 00:00:002020-12-11 00:00:00Antitumor Activity of Curcumin in Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / Int J Hyperthermia 2020 07;37(2):3-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / Int J Hyperthermia 2020 07;37(2):3-192020-07-01 00:00:002020-07-01 00:00:00Hyperthermia treatment advances for brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-3032020-06-24 00:00:002021-05-12 07:29:51CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model
